Aqua Medical Appoints Bob Haggerty to Lead Diabetes Growth
Pleasanton, California, August 4, 2026 Aqua Medical, Inc. has announced the appointment of Robert “Bob” Haggerty as President and...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Pleasanton, California, August 4, 2026 Aqua Medical, Inc. has announced the appointment of Robert “Bob” Haggerty as President and...
PLEASANTON, Calif., July 28, 2026 Aqua Medical, Inc. has achieved a major clinical milestone with the successful treatment of...
